J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance
Executive Summary
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability
You may also be interested in...
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
Xarelto Action Letter No Surprise; But Does FDA Want Data, REMS Or Both?
As anticipated, FDA answered Johnson & Johnson/Bayer's NDA for anticoagulant Xarelto (rivaroxaban) with a complete response letter May 28